U.S. pharmaceutical lobby group PhRMA said on Monday it will launch a new website in January 2026 to help patients buy prescription drugs directly from manufacturers, bypassing pharmacy benefit ...
At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...
FDA approves Johnson & Johnson's Tremfya for children with plaque psoriasis and psoriatic arthritis. Read more here.
Key Takeaways FDA has launched an aggressive new crackdown on direct-to-consumer (DTC) drug advertising, issuing nearly 100 cease-and-desist letters and thousands of notices — many targeting ...
On5, 2025, President Donald J. Trump issued National Security Presidential Memorandum 7 (NSPM‑7), a memorandum entitled “Countering Domestic Terrorism and Organized Political Violence.” While the ...
The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...
An emergency fund can help you take care of said expensess without falling into debt or dipping into your retirement savings.
The FDA has approved Johnson & Johnson’s TREMFYA for children aged 6+ weighing at least 40 kg with moderate to severe plaque ...
The approval for plaque PsO was based on data from the PROTOSTAR trial, which evaluated guselkumab in participants aged 6 to 17 years with moderate to severe plaque PsO.
Patients with D2T-PsA can be stratified into inflammatory and noninflammatory phenotypes, with the former linked to higher sonographic activity.
Most children with JPsA show improved disease activity over the first 2 years of treatment, despite requiring early systemic therapy.
On Monday, the FDA approved guselkumab (Tremfya; Johnson & Johnson) for the treatment of children 6 and older who also weigh at least 40 kg with plaque psoriasis (PsO) and active psoriatic arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback